SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-23-010854
Filing Date
2023-08-15
Accepted
2023-08-15 16:05:33
Documents
15
Period of Report
2023-08-09
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tenx_8k.htm   iXBRL 8-K 23858
2 FOURTH AMENDED AND RESTATED BYLAWS tenx_ex31.htm EX-3.1 117715
  Complete submission text file 0001654954-23-010854.txt   291670

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tenx-20230809.xsd EX-101.SCH 5720
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20230809_lab.xml EX-101.LAB 15214
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20230809_cal.xml EX-101.CAL 898
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20230809_pre.xml EX-101.PRE 9640
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20230809_def.xml EX-101.DEF 2099
9 EXTRACTED XBRL INSTANCE DOCUMENT tenx_8k_htm.xml XML 3724
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 231174881
SIC: 2834 Pharmaceutical Preparations